Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Sangui BioTech International Inc.: - Sales of USD 55,367 in the first half-year; Strong year-end-business

EQS Group Thursday, 14 February 2019
DGAP-News: Sangui BioTech International Inc. / Key word(s): Half Year Results

14.02.2019 / 10:24
The issuer is solely responsible for the content of this announcement.
-------------------- 

*Sangui BioTech:*

*- Sales of USD 55,367 in the first half-year*

*- Strong year-end-business*Witten, February, 14 2019: In the first six months of fiscal year 2019 (to 30/06/2019) Sangui BioTech International Inc. achieved revenues from royalty income of USD 55,367. In the same period of the previous year the comparable revenue amounted to USD 55,082. Due to only slightly higher revenues of the wound spray Granulox, the resulting royalty income in the first half of the year remained at the level of the same period of the previous year.

While the first quarter lagged behind the previous year, royalty income in the second quarter clearly exceeded those of the prior-year period. For example, the strong year-end business in 2018 led to a rise in second-quarter royalty income revenues of USD 5,646 or 15% compared to the previous year.

As operating expenses increased USD 44,740 or 27% to USD 208,903 during the period, first half years operating loss increased USD 44,510 to USD 153,635 from the prior year. The operating loss for the second quarter of 2019, on the other hand, increased disproportionately by USD 8,801 compared to the previous year to USD 60,137.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
--------------------

14.02.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
0
shares
ShareTweetSavePostSend
 

Recent related news from verified sources

Flexible Solutions International shares jump on news of annual dividend

Flexible Solutions International Inc (NYSEMKTS:FSI) shares jumped on Wednesday after news that the company will be introducing an annual dividend of US$0.15 per...
Proactive Investors

NORMA Group increases its sales to around EUR 1.1 billion in 2018

DGAP-News: NORMA Group SE / Key word(s): Annual Results/Dividend 20.03.2019 / 07:56 The issuer is solely responsible for the content of this announcement. ...
EQS Group

Horizon Marijuana Life Sciences Index bolstered with new additions

A number of new cannabis players were added to the quarterly rebalance of the Horizon Marijuana Life Sciences Index (HMMJ) ETF on Monday. HMMJ bolstered its...
Proactive Investors

Uniview 2018 Annual Report: 607 Million USD Revenue, 31.3% Growth Rate

HANGZHOU, China, March 21, 2019 /PRNewswire/ -- Uniview released the annual financial report of 2018, achieving 607 million USD revenue and 31.3% year-on-year...
PR Newswire Asia

You Might Like


Tweets about this


Other recent news in Press Releases

Jason Borrevik Scholarship for BUSINESS, Law, & Economics StudentsDiscover the Most Diverse Designs of Lifestyle PRODUCTS at STYLE Bangkok
Silver Range Resources Ltd. Closes Private Placement and Begins Exploration in NEVADAFindit, Inc. Offers Video Production to Increase and Improve SEARCH Ranking and Social Media Engagement
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.